Division of Cardiology, University of Basel, Switzerland.
J Am Coll Cardiol. 2012 Apr 17;59(16):1426-37. doi: 10.1016/j.jacc.2011.12.033.
This study sought to assess whether plasminogen, which is homologous to lipoprotein (a) [Lp(a)], contains proinflammatory oxidized phospholipids (OxPL) and whether this has clinical relevance.
OxPL measured on apolipoprotein B-100 (OxPL/apoB), primarily reflecting OxPL on Lp(a), independently predict cardiovascular disease (CVD) events.
The authors examined plasminogen from commercially available preparations and plasma from chimpanzees; gorillas; bonobos; cynomolgus monkeys; wild-type, apoE(-/-), LDLR(-/-), and Lp(a)-transgenic mice; healthy humans; and patients with familial hypercholesterolemia, stable CVD, and acute myocardial infarction (AMI). Phosphocholine (PC)-containing OxPL (OxPC) present on plasminogen were detected directly with liquid chromatography-mass spectrometry (LC-MS/MS) and immunologically with monoclonal antibody E06. In vitro clot lysis assays were performed to assess the effect of the OxPL on plasminogen on fibrinolysis.
LC-MS/MS revealed that OxPC fragments were covalently bound to mouse plasminogen. Immunoblot, immunoprecipitation, density gradient ultracentrifugation, and enzyme-linked immunosorbent assay analyses demonstrated that all human and animal plasma samples tested contained OxPL covalently bound to plasminogen. In plasma samples subjected to density gradient fractionation, OxPL were present on plasminogen (OxPL/plasminogen) in non-lipoprotein fractions but on Lp(a) in lipoprotein fractions. Plasma levels of OxPL/apoB and OxPL/apo(a) varied significantly (>25×) among subjects and also strongly correlated with Lp(a) levels. In contrast, OxPL/plasminogen levels were distributed across a relatively narrow range and did not correlate with Lp(a). Enzymatic removal of OxPL from plasminogen resulted in a longer lysis time for fibrin clots (16.25 vs. 11.96 min, p = 0.007). In serial measurements over 7 months, OxPL/plasminogen levels did not vary in normal subjects or in patients with stable CVD, but increased acutely over the first month and then slowly decreased to baseline in patients following AMI.
These data demonstrate that plasminogen contains covalently bound OxPL that influence fibrinolysis. OxPL/plasminogen represent a second major plasma pool of OxPL, in addition to those present on Lp(a). OxPL present on plasminogen may have pathophysiological implications in AMI and atherothrombosis.
本研究旨在评估纤溶酶原是否含有促炎氧化磷脂(OxPL),以及其是否具有临床相关性。
载脂蛋白 B-100 上的 OxPL(OxPL/apoB)主要反映脂蛋白(a)[Lp(a)]上的 OxPL,可独立预测心血管疾病(CVD)事件。
作者检测了市售制剂中的纤溶酶原和黑猩猩、大猩猩、倭黑猩猩、食蟹猴、野生型、载脂蛋白 E 缺失型、低密度脂蛋白受体缺失型和 Lp(a)-转基因小鼠、健康人类以及家族性高胆固醇血症、稳定型 CVD 和急性心肌梗死(AMI)患者的血浆。使用液相色谱-质谱法(LC-MS/MS)和单克隆抗体 E06 直接检测纤溶酶原上的磷酸胆碱(PC)含量氧化的 OxPL(OxPC)。进行体外血栓溶解试验以评估 OxPL 对纤溶酶原的纤维蛋白溶解的影响。
LC-MS/MS 显示 OxPC 片段与小鼠纤溶酶原发生共价结合。免疫印迹、免疫沉淀、密度梯度超速离心和酶联免疫吸附试验分析表明,所有测试的人类和动物血浆样本均含有与纤溶酶原共价结合的 OxPL。在进行密度梯度分级分离的血浆样本中,OxPL 存在于非脂蛋白部分的纤溶酶原(OxPL/plasminogen)上,但存在于脂蛋白部分的 Lp(a)上。OxPL/apoB 和 OxPL/apo(a)的血浆水平在受试者之间差异很大(>25 倍),并且与 Lp(a)水平也呈强烈相关性。相比之下,OxPL/plasminogen 水平分布范围较窄,与 Lp(a)不相关。从纤溶酶原中酶切去除 OxPL 会导致纤维蛋白血栓的溶解时间延长(16.25 分钟比 11.96 分钟,p=0.007)。在 7 个月的连续测量中,正常受试者或稳定型 CVD 患者的 OxPL/plasminogen 水平没有变化,但在 AMI 患者中,该水平在第一个月内急剧升高,然后缓慢降至基线。
这些数据表明,纤溶酶原含有影响纤维蛋白溶解的共价结合 OxPL。OxPL/plasminogen 是除 Lp(a)之外的 OxPL 的另一个主要血浆池。存在于纤溶酶原上的 OxPL 可能在 AMI 和动脉血栓形成中具有病理生理学意义。